NFE2L2 and breast carcinoma: The importance of NRF2 in chemoresistance of breast cancer cells was further substantiated in a recent study wherein NRF2 activation in response to hypoxia-induced ROS accumulation conferred an insensitivity to cisplatin in MCF-7 cells [44].